All In Biotech

Drug Trial Radar · NCT07155499

A Clinical Trial for Evaluation of Efficacy, Safety and Immunogenicity of GNR-127 (Recombinant ABP Antigen Protein Which Carries a Birch Pollen Allergen [BET V 1] and an Apple Allergen [MAL D 1]) in Patients With Birch Pollen Allergic Rhinitis.

A Two-stage Clinical Trial With Dose Escalation at the First Stage and a Single-blind, Placebo-controlled Clinical Trial for Evaluation of Efficacy, Safety, Reactogenicity and Immunogenicity of GNR-127 at the Second Stage in Patients With Allergic Rhinitis Sensitized to Birch Pollen.

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

150

Actual

Start

Oct 7, 2024

Primary completion

May 31, 2025

Study completion Sep 8, 2025

Sponsor

Lead sponsor
AO GENERIUMIndustry
Sponsor type
Industry
First posted
Sep 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is first-in-human phase 1/2 clinical trial to evaluate the safety, systemic and local reactogenicity of GNR-127 at the first stage in sequential cohorts of patients with allergic rhinitis with sensitization to the birch pollen, and then to determine and evaluate an effective and safe dose of the GNR-127 after five monthly administrations compared to placebo at the second stage.

Conditions

  • Rhinitis, Allergic, Seasonal

Interventions

  • GNR-127, 20 mcgBiological

    GNR-127, 20 mcg in 0.5 ml administered 5 times every 4 weeks

  • GNR-127, 40 mcgBiological

    GNR-127, 40 mcg in 0.5 ml administered 5 times every 4 weeks

  • GNR-127, 80 mcgBiological

    GNR-127, 80 mcg in 0.5 ml administered 5 times every 4 weeks

  • GNR-127 placeboBiological

    GNR-127 placebo 0.5 ml administered 5 times every 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Daily Symptom Score (dSS)Time frame: Up to 3 months after the end of treatment.
  2. Daily Medication Score (dMS)Time frame: Up to 3 months after the end of treatment.
  3. Combined Symptom and Medication Score (CSMS)Time frame: Up to 3 months after the end of treatment.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Research Center - Institute of Immunology Federal Medical-Biological Agency

    Moscow, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.